Safety and effectiveness of adalimumab in patients with rheumatoid arthritis over 5 years of therapy in a phase 3b and subsequent postmarketing observational study

Eitemau Tebyg

• Adalimumab alone and in combination with disease‐modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial
  gan: Burmester, Gerd R, et al.
  Cyhoeddwyd: (2007)
• An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status
  gan: van der Bijl, Arie E., et al.
  Cyhoeddwyd: (2008)
• Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis
  gan: Schiff, M H, et al.
  Cyhoeddwyd: (2006)
• Effectiveness of adalimumab in treating patients with ankylosing spondylitis associated with enthesitis and peripheral arthritis
  gan: Rudwaleit, Martin, et al.
  Cyhoeddwyd: (2010)
• Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy
  gan: Rudwaleit, Martin, et al.
  Cyhoeddwyd: (2010)